Baird Positive on Celgene (CELG) As Pancreatic Cancer Drug Shows Promise
Tweet Send to a Friend
A recent report by Baird suggests big potential for Celgene Corporation's (Nadaq: CELG) Abraxane in pancreatic cancer. Prior to recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
